Assignment to New Technology APC 1580 is positive news for Nyxoah’s US commercial rollout.
The US Centers for Medicare & Medicaid Services (CMS) has finalized its CY2026 Hospital Outpatient Prospective Payment System and Ambulatory Surgery Center (ASC) Rule. Within the final rule, CMS assigned CPT 64568, the code used for all Nyxoah SA Genio hypoglossal nerve stimulation implants, to New Technology Ambulatory Payment Classification 1580.
Effective January 1, 2026, Hospital Outpatient Department reimbursement for CPT 64568 will increase to approximately $45,000, a 48% rise compared to 2025. In addition, ambulatory surgery centers facility reimbursement will increase to $42,373, reflecting a 58% increase compared to 2025.
These updates apply uniformly to all procedures billed under CPT 64568, including Genio, and strengthen the economic foundation supporting therapy adoption across US hospital outpatient departments and ambulatory surgical centers. With CMS’s decision, Genio enters 2026 with a stronger reimbursement framework that is expected to support broader adoption, increased procedural throughput, and expansion across Medicare-heavy institutions.
According to Nyxoah, Genio’s single-incision procedure is well-suited for the ambulatory surgery center environment, and the significant increase in facility payment creates new opportunities for therapy expansion and site-of-service diversification.
“CMS’ decision to significantly increase reimbursement for CPT 64568 reinforces the growing recognition of hypoglossal nerve stimulation as a high-value therapy for obstructive sleep apnea,” says Olivier Taelman, Nyxoah’s CEO, in a release. “The new rates create a more favorable environment for expanding access to our Genio therapy across both outpatient hospitals and [ambulatory surgery centers].”
